SmallCapReview.com is a leading small cap stock information site since 1999, to register for the free SmallCapReview newsletter visit http://www.smallcapreview.com.
North American Energy Resources (OTCBB: NAEY) $0.37. Announced last week that is has entered into a letter of intent to acquire a 20% interest in Washington Gathering System. The transaction is anticipated to close on or before August 31, 2009. Washington Gathering System currently serves all the natural gas production in NAEY's area of interest in Northern Oklahoma.
What They Do: North American Energy Resources, Inc. is an oil and gas development company focused on building a diversified portfolio of valuable oil and gas assets in the United States. The company's primary goal is to identify, acquire and develop natural gas and oil properties that are relatively close to NAEY's Apwash pipeline in Washington County, Oklahoma.
BP $51.20 and Martek Biosciences Corporation (Nasdaq: MATK) $23.85. Today announced the signing of a Joint Development Agreement (JDA) to work on the production of microbial oils for biofuels applications. The partnership combines a broad technology platform and operational capabilities to advance the development of a step-change technology for the conversion of sugars into biodiesel.
Under the terms of the multi-year agreement, Martek and BP will work together to establish proof of concept for large-scale, cost effective microbial biodiesel production through fermentation.
What They Do: Martek Biosciences Corporation is a leader in the development and production of high-value oils from algae and other microbial sources. Martek's lead products are DHA and ARA oils developed and produced using patented technology.
What They Do: BP is of one of the world's largest energy companies, providing its customers with fuel for transportation, energy for heat and light, retail services and petrochemicals products for everyday items. It is the largest oil and gas producer in the U.S. and one of the largest refiners. BP also has a global network of around 22,000 service stations.
Anadys Pharmaceuticals (Nasdaq: ANDS) $2.39. Today announced viral load data for the final cohort of hepatitis C patients in a Phase I clinical trial of ANA773, the Company's oral inducer of endogenous interferons that acts via the toll-like receptor 7 (TLR7) pathway. In patients who received 2000 mg ANA773 every other day over 10 days, the mean (+/-SEM) maximal decline in viral load was 1.3 (+/-0.4) log10, compared to a mean maximal decline of 0.3 (+/-0.1) log10 in patients who received placebo (p=0.037). Five of the eight patients who received 2000 mg ANA773 experienced a maximal decline of greater than 1 log, while none of the eight patients who received placebo experienced a decline of greater than 1 log (p<0.001 for the proportion of patients with maximal response greater than 1 log compared to placebo). The mean end-of-treatment decline was 0.6 log10 in patients who received 2000 mg ANA773 compared to 0.1 log10 in patients who received placebo. ANA773 was well-tolerated in patients throughout the course of the study and there were no serious adverse events reported.
What They Do: Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com/. SCR has been compensated up to three thousand five hundred dollars by a third party APS for its services with regards to North American Energy Resources.
